NCT03261427View on ClinicalTrials.gov

Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

October 11, 2017

Study Completion Date

March 29, 2018

Conditions
Healthy
Interventions
DRUG

Lyrica 150Mg Capsule

150 mg oral administered (BID)

DRUG

YNP-1807 330Mg Tablet

330 mg oral administered (QD)

Trial Locations (1)

120-752

Severance Hospital, Seoul

All Listed Sponsors
lead

Yungjin Pharm. Co., Ltd.

INDUSTRY

NCT03261427 - Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration Adult Volunteers | Biotech Hunter | Biotech Hunter